Monographie - Remifentanil hydrochloride

Son güncelleme :
28/04/2024

Remifentanil hydrochloride

Kimyasal yapı

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Fenburol	Güney Afrika Cumhuriyeti, Şili
Proximicil	Meksika
Redormin	Arjantin
Remicit	Arjantin
Remifas	Ekvador
Remifentanil	Almanya, Belçika, İzlanda, Kanada, Norveç, Romanya, Yeni Zelanda
Remifentanilo	Arjantin, İspanya, Portekiz
Remiflo	Arjantin
Remimed	Almanya
Restinil	Arjantin, Ekvador
Sagal	Arjantin
Ultiva	Almanya, Amerika Birleşik Devletleri, Avustralya, Avusturya, Belçika, Büyük Britanya, Danimarka, Ekvador, Finlandiya, Fransa, Hollanda, İran, İrlanda, İspanya, İsveç, İsviçre, İtalya, Kolombiya, Lüksemburg, Macaristan, Malezya, Mısır, Norveç, Peru, Polonya, Portekiz, Romanya, Şili, Suudi Arabistan, Tunus, Türkiye, Venezuela, Yeni Zelanda, Yunanistan

Kaynaklar : Remifentanil hydrochloride

	Tip	Yayın
59	Dergi	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
921	Dergi	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1506	Dergi	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Dergi	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1712	Dergi	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1803	Dergi	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Dergi	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
2141	Dergi	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2269	Dergi	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2325	Dergi	Nemec K, Germ E, Schulz-Siegmund M, Ortner A. The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions. Pharmazie 2009 ; 64, 2: 94-97.
3176	Afiş	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3249	Dergi	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3294	Dergi	Humbert-Delaloye V, Berger M, Voirol P, Pannatier A. In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs EJHP 2012 ; 19: 57-64.
3372	Dergi	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3504	Laboratuar	Parecoxib (Dynastat®) - Summary of Product Characteristics Pfizer 2012
3519	Laboratuar	Remifentanil hydrochloride(Ultiva®) - Summary of Product Characteristics Glaxo Smith Kline 2011
3781	Dergi	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58
3823	Dergi	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
4011	Dergi	Gersonde F, Eisend S, Haake N, Kunze T. Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit. EJHP 2016 2016;0:1-11
4183	Afiş	Hook R, Riss V, Scharrer E, Law S, Walker S.E. Stability if 4 and 10 mcg/mL Remifentanil Solutions Stored in Syringes at Room Temperature (23°C). Professional Practice Conference - the Canadian So 2018
4192	Dergi	Bourdon F, Simon N, Lannoy D, Berneron C, D?caudin B, Reumaux L, Duhamel A, Richart P, Odou P. Quality control and stability of ketamine, remifentanil and sufentanil syringes in a pediatric operating theater. Pediatric Anesthesia 2018
4231	Afiş	Roxanne Hook, Vera Riss, Erica Scharrer, Shirley Law and Scott E. Walker Stability of 4 and 10 mcg/mL Remifentanil Solutions Stored in Syringes at Room Temperature (23°C) Professional Practice Conference - Canadian Societ 2018
4331	Dergi	Nilsson N, Nezvalova-Henriksen K, Tho I. Emulsion Stability of Different Intravenous Propofol Formulations in Simulated Co-Administration with Remifentanil Hydrochloride. Pharmaceutical Technology in Hospital Pharmacy 2019
4389	Dergi	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4501	Dergi	Henkel E, Vella R, Behan K, Austin D, Kruger P, Fenning A. The effect of concentration, reconstitution solution and pH on the stability of a remifentanil hydrochloride and propofol admixture for simultaneous co-infusion. BMC Anesthesiology 2020 ;20:283.
4650	Laboratuar	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4698	Dergi	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4723	Dergi	Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. Am J Health-Syst Pharm 2022 https://doi.org/10.1093/a
4742	Dergi	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales